India’s largest drug maker Ranbaxy Laboratories has reconstituted its board. This follows the ownership change in Ranbaxy after Japanese drug firm Daiichi Sankyo Company acquired 63.92 per cent stake in the company.
Malvinder Mohan Singh, Ranbaxy CEO and MD will be the chairman of the nine member board, which will have Takashi Shoda, president & CEO of Daiichi Sankyo as a member.
The other members of the board are Ranbaxy COO Atul Sobti, Daiichi board member Tsutomu Une, Religare CEO and MD Sunil Godhwani, BOWS Pharmaceuticals' Anthony H Wild, Mukand Ltd's Rajesh V Shah, GCA Savvian Group's Akihiro Watanabe and Balinder Singh Dhillon.
Malvinder Mohan Singh has also become a member of the senior global management team of Daiichi Sankyo.
Subsequent to the reconstitution of Ranbaxy’s board, several committees of the board including the audit, remuneration and shareholder/investors committees have also been reconstituted.
Top Section
Explore Business Standard